Natera (NASDAQ:NTRA) Given New $165.00 Price Target at Canaccord Genuity Group

Natera (NASDAQ:NTRA) had its price objective lifted by Canaccord Genuity Group from $150.00 to $165.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other equities analysts have also recently issued reports on NTRA. TD Cowen increased their price objective on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley raised their price target on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price target on shares of Natera in a research report on Friday, September 13th. Leerink Partners raised their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Sanford C. Bernstein raised their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $135.06.

Natera Stock Performance

Shares of NTRA opened at $160.97 on Wednesday. The stock has a market capitalization of $19.91 billion, a P/E ratio of -91.46 and a beta of 1.53. The firm’s fifty day simple moving average is $126.04 and its two-hundred day simple moving average is $114.84. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera has a 12 month low of $49.97 and a 12 month high of $167.79.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. The business’s revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.95) EPS. As a group, analysts predict that Natera will post -1.96 EPS for the current year.

Insider Buying and Selling

In related news, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the transaction, the insider now directly owns 284,741 shares of the company’s stock, valued at approximately $36,324,409.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Natera news, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the transaction, the insider now directly owns 284,741 shares of the company’s stock, valued at $36,324,409.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,881 shares of company stock valued at $3,733,983. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Castle Hook Partners LP boosted its holdings in Natera by 27.4% in the 3rd quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock valued at $144,734,000 after purchasing an additional 245,505 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Natera by 5.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company’s stock worth $3,344,000 after acquiring an additional 1,263 shares during the last quarter. Cynosure Group LLC bought a new stake in shares of Natera during the 3rd quarter worth $370,000. Brooklyn Investment Group bought a new stake in shares of Natera during the 3rd quarter worth $70,000. Finally, Millrace Asset Group Inc. lifted its holdings in shares of Natera by 22.5% during the 3rd quarter. Millrace Asset Group Inc. now owns 12,144 shares of the medical research company’s stock worth $1,542,000 after acquiring an additional 2,228 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.